Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Lassen Ther­a­peu­tics closed an over­sub­scribed $85 mil­lion Se­ries B on Tues­day morn­ing as the San Diego biotech brings its treat­ment can­di­date for thy­roid eye dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER